PDCD1 and non-small cell lung carcinoma: Extrapolating our observations to human cancers, a conversion of immune-resistant NSCLC into tumors responsive to ICIs would have the potential to convert patients who do not respond to anti-PD-1 therapy into responders, thereby making checkpoint blockade clinically beneficial for a larger proportion of advanced NCSLC patients.